Them Witches
Bluelighter
- Joined
- Apr 21, 2025
- Messages
- 797
This past week I was in ICU for 4 days and given Precedex by continuous infusion. I was given a higher dosage than normal due to my tolerance to Clonidine. Precedex is a very clean feeling sedative that produces a positive mental state, free of stress, despite not feeling well or having to remain in a fixed position. I was also PRN a high dosage of Diluadid with my normal PO pain meds, benzo, alpha-2, and sedative/hypnotics. If you are one of those patients that becomes irritated being in a hospital or has GAD, asking for Precedex would be helpful.
Precedex (dexmedetomidine hydrochloride) is a sedative/hypnotic agent classified therapeutically as an alpha2-adrenergic agonist. Used for intensive care unit (ICU) sedation and procedural sedation, it provides sedative and analgesic effects without typically causing significant respiratory depression.
Dexmedetomidine is a highly selective α2-adrenergic receptor agonist. It possesses an α2:α1 selectivity ratio of 1620:1, making it 8 times more selective for the α2-adrenergic receptor than the related drug clonidine. Dexmedetomidine induces sedation by decreasing activity of noradrenergic neurons in the locus ceruleus in the brain stem, thereby increasing the downstream activity of inhibitory γ-aminobutyric acid (GABA) neurons in the ventrolateral preoptic nucleus. In contrast, other sedatives like propofol and benzodiazepines directly increase activity of GABAergic neurons. Through action on this endogenous sleep-promoting pathway the sedation produced by dexmedetomidine more closely mirrors natural sleep (specifically stage 2 non-rapid eye movement sleep (NREM)), as demonstrated by EEG studies. As such, dexmedetomidine provides less amnesia than benzodiazepines. Dexmedetomidine also has analgesic effects at the spinal cord level and other supraspinal sites
Precedex (dexmedetomidine hydrochloride) is a sedative/hypnotic agent classified therapeutically as an alpha2-adrenergic agonist. Used for intensive care unit (ICU) sedation and procedural sedation, it provides sedative and analgesic effects without typically causing significant respiratory depression.
Dexmedetomidine is a highly selective α2-adrenergic receptor agonist. It possesses an α2:α1 selectivity ratio of 1620:1, making it 8 times more selective for the α2-adrenergic receptor than the related drug clonidine. Dexmedetomidine induces sedation by decreasing activity of noradrenergic neurons in the locus ceruleus in the brain stem, thereby increasing the downstream activity of inhibitory γ-aminobutyric acid (GABA) neurons in the ventrolateral preoptic nucleus. In contrast, other sedatives like propofol and benzodiazepines directly increase activity of GABAergic neurons. Through action on this endogenous sleep-promoting pathway the sedation produced by dexmedetomidine more closely mirrors natural sleep (specifically stage 2 non-rapid eye movement sleep (NREM)), as demonstrated by EEG studies. As such, dexmedetomidine provides less amnesia than benzodiazepines. Dexmedetomidine also has analgesic effects at the spinal cord level and other supraspinal sites
